Pembrolizumab induced pneumonitis
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Daniel J Bell had no recorded disclosures.View Daniel J Bell's current disclosures
Pembrolizumab induced pneumonitis is a form of drug-induced lung disease occurring as a result of a response to the use of the programmed cell death protein 1 (PD1) inhibitor pembrolizumab. It may have variable pattern 2.
Pembrolizumab is also reported to have a high risk of inducing lung injury in patients with pre-existing interstitial lung disease 3.
- 1. Fujita T, Hayama N, Kuroki T et al. Pembrolizumab-Induced Interstitial Lung Disease Following Thoracic Surgery in a Patient with Non-Small Cell Lung Cancer. Thorac Cancer. 2019;10(11):2179-82. doi:10.1111/1759-7714.13194 - Pubmed
- 2. Ueno R, Nemoto M, Uegami W, Fukuoka J, Misawa M. Pembrolizumab-Induced Pneumonitis with a Perilymphatic Nodular Pattern in a Lung Cancer Patient: A Radio-Pathologic Correlation. Respiratory Medicine Case Reports. 2019;26:168-70. doi:10.1016/j.rmcr.2019.01.001 - Pubmed
- 3. Fujita T, Kuroki T, Hayama N et al. Pembrolizumab for Previously Untreated Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease. Intern Med. 2020;59(16):1939-45. doi:10.2169/internalmedicine.4552-20 - Pubmed